Analysts have been eager to weigh in on the Healthcare sector with new ratings on Roche Holding AG (RHHVF – Research Report), MacroGenics (MGNX – Research Report) and Alkermes (ALKS – Research Report).
Roche Holding AG (RHHVF)
UBS analyst Matthew Weston maintained a Hold rating on Roche Holding AG today and set a price target of CHF238.00. The company’s shares closed last Monday at $242.58, close to its 52-week low of $233.12.
According to TipRanks.com, Weston is ranked #1655 out of 8841 analysts.
Roche Holding AG has an analyst consensus of Hold, with a price target consensus of $283.25.
See Insiders’ Hot Stocks on TipRanks >>
MacroGenics (MGNX)
In a report issued on May 9, Jonathan Chang from Leerink Partners maintained a Buy rating on MacroGenics, with a price target of $8.00. The company’s shares closed last Monday at $4.38, close to its 52-week low of $3.14.
According to TipRanks.com, Chang is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on MacroGenics is a Moderate Buy with an average price target of $14.56, a 314.8% upside from current levels. In a report issued on April 25, B.Riley Financial also initiated coverage with a Buy rating on the stock with a $25.00 price target.
Alkermes (ALKS)
In a report issued on May 9, Uy Ear from Mizuho Securities maintained a Buy rating on Alkermes, with a price target of $35.00. The company’s shares closed last Monday at $24.71.
According to TipRanks.com, Ear is a 3-star analyst with an average return of
Alkermes has an analyst consensus of Moderate Buy, with a price target consensus of $33.64, implying a 38.6% upside from current levels. In a report issued on May 2, Goldman Sachs also maintained a Buy rating on the stock with a $32.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RHHVF:
